-
Cerebrospinal Fluid Amyloid and Tau Biomarker Changes Across the Alzheimer Disease Clinical Spectrum
de Leeuw, D. M., Trieu, C., Vromen, E. M., Blujdea, E. R., Verberk, I. M. W., Duits, F. H., Teunissen, C. E., Pijnenburg, Y. A. L., van der Flier, W. M., van Harten, A. C., Visser, P. J. & Tijms, B. M., 1 Jul 2025, In: JAMA Network Open. 8, 7, p. e2519919Research output: Contribution to journal › Article* › Academic › peer-review
-
Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting
Wimo, A., Handels, R., Blennow, K., Kirsebom, B.-E., Selnes, P., Bon, J., Emersic, A., Gonzalez-Ortiz, F., Gregoric Kramberger, M., Sköldunger, A., Speh, A., Timón-Reina, S., Vromen, E., Jelle Visser, P., Winblad, B. & Fladby, T., 1 Apr 2025, In: Journal of Alzheimer s disease. 104, 4, p. 1167-1184 18 p.Research output: Contribution to journal › Article* › Academic › peer-review
-
Unraveling Alzheimer's disease heterogeneity: a deep dive into the cerebrospinal fluid proteome
Vromen, E. M., 31 Jan 2025, 241 p.Research output: PhD thesis › Thesis, fully internal
- All publications
